igf-methotrexate
Recombinant proteinexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 28, 2014 (NCT02045368)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Anemia, Refractory, with Excess of Blasts · Phase 1/Phase 2
- Brain Neoplasms · Phase 1
- Breast Neoplasms · Phase 1
- Gastrointestinal Neoplasms · Phase 1
- Genital Neoplasms, Female · Phase 1
- Leukemia, Myelomonocytic, Chronic · Phase 1/Phase 2
- Melanoma · Phase 1
- Myelodysplastic Syndromes · Phase 1/Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 1
- Thoracic Neoplasms · Phase 1
- Urogenital Neoplasms · Phase 1
Mechanism of action
IGF1R agonist
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- igf-methotrexate
- igf/mtx
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03175978 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2017 | IGF Oncology, LLC, Mayo Clinic |
| NCT02045368 | Phase 1 | Jan 28, 2014 | IGF Oncology, LLC, University of Illinois at Chicago |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| IGF Oncology, LLC | For profit | 2 | 2 | 2 | 2014 |
| Mayo Clinic | Academic/Hospital | 1 | 0 | 1 | 2017 |
| University of Illinois at Chicago | Academic/Hospital | 1 | 0 | 1 | 2014 |
3 organizations
Page 1 / 1